Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of BGB-11417 in Participants With Myeloid Malignancies
Sponsor: BeiGene
Summary
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
Official title: A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
260
Start Date
2021-05-24
Completion Date
2028-02-08
Last Updated
2026-03-04
Healthy Volunteers
No
Conditions
Interventions
BGB-11417
Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.
Azacitidine
Intravenous or subcutaneous administration for 7 days.
Posaconazole
Oral administration for 8 days on second cycle only.
BGB-11417
Oral administration for 28 days on a 28-day cycle.
BGB-11417
Oral administration for 10, 14 or 21 days on a 28-day
Locations (46)
City of Hope National Medical Center
Duarte, California, United States
Tampa General Hospital
Tampa, Florida, United States
Upmc Hillman Cancer Center(Univ of Pittsburgh)
Pittsburgh, Pennsylvania, United States
Md Anderson Cancer Center
Houston, Texas, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Concord Repatriation General Hospital
Concord, New South Wales, Australia
St George Hospital
Kogarah, New South Wales, Australia
Orange Health Hospital
Orange, New South Wales, Australia
Gold Coast University Hospital
Southport, Queensland, Australia
Monash Health
Clayton, Victoria, Australia
St Vincents Hospital Melbourne
Fitzroy, Victoria, Australia
Austin Health
Heidelberg, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
One Clinical Research
Nedlands, Western Australia, Australia
Peking University Peoples Hospital
Beijing, Beijing Municipality, China
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
Guangdong Provincial Peoples Hospital
Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
The Second Peoples Hospital of Shenzhen
Shenzhen, Guangdong, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Hopital Claude Huriez Chu Lille
Lille, France
Hopital Larchet
Nice, France
Hopital Saint Louis
Paris, France
Universitaetsklinikum Leipzig Aor
Leipzig, Germany
Universitaetsklinikum Ulm
Ulm, Germany
Policlinico Sorsola Malpighi, Aou Di Bologna
Bologna, Italy
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst
Meldola, Italy
Niguarda Cancer Center Division of Hematology
Milan, Italy
North Shore Hospital
Auckland, New Zealand
Wellington Regional Hospital (Ccdhb)
Wellington, New Zealand
Samsung Medical Center
GangnamGu, Seoul Teugbyeolsi, South Korea
Severance Hospital Yonsei University Health System
SeodaemunGu, Seoul Teugbyeolsi, South Korea
Hospital de La Santa Creu I Sant Pau
Barcelona, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Hospital Universitario Virgen Del Rocio
Seville, Spain
Hospital Universitari I Politecnic La Fe
Valencia, Spain
Edinburgh Cancer Centre
Edinburgh, United Kingdom
The Christie Hospital
Greater Manchester, United Kingdom